Inhibitor Therapeutics, Inc.

Item 5.07 Submission of Matters to a Vote of Security Holders. On September 15, 2026, Inhibitor Therapeutics, Inc., a Delaware corporation (the “ Company ”) held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”). At the Annual Meeting, the Company’s stockholders voted on the following three proposals: Proposal 1 - Election of Directors Francis E. O’Donnell, Samuel J. Sears, Niraj Vasisht, Michelle Yanez, Michael Jerman and Ronald E. Osman were each elected to serve on the Board of Directors (the “ Board ”) for a one-year term that expires at the 2027 Annual Meeting of Stockholders, or until their earlier death, resignation or removal and their successors are elected and qualified. The final results of the voting were as follows: Director Nominee Votes For Withheld Broker Non-Votes ─────────────────────────────────────────────────────────────────────── Francis E. O’Donnell 96,676,056 2,783,870 12,986,028 Samuel J. Sears 96,676,056 2,783,870 12,986,028 Niraj Vasisht 96,676,056 2,783,870 12,986,028 Michelle Yanez 98,342,951 1,116,975 12,986,028 Ronald E. Osman 96,676,056 2,783,870 12,986,028 Michael Jerman 98,342,951 1,116,975 12,986,028 Proposal 2 - Auditor Ratification The Company’s stockholders ratified the previous appointment by the Board of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final results of the voting were as follows: Votes For Votes Against Abstentions Broker Non-Votes ────────────────────────────────────────────────────────────────── 110,776,019 1,668,434 1,501 - Proposal 3 - Incentive Plan The Company’s stockholders approved the 2025 Share Incentive Plan. The final results of the voting were as follows: Votes For Votes Against Abstentions Broker Non-Votes ────────────────────────────────────────────────────────────────── 96,249,721 3,208,603 1,602 12,986,028 Proposal 4 - Say-on-Pay The Company’s executive compensation, by non-binding advisory vote, was approved. The final results of the voting were as follows: Votes For Votes Against Abstentions Broker Non-Votes ────────────────────────────────────────────────────────────────── 96,854,767 2,605,058 101 12,986,028 Proposal 5 - Frequency of Non-Binding Advisory Votes on Executive Compensation The Company’s stockholders indicated, on an advisory basis, the preferred frequency of future non-binding advisory votes on the compensation of the Company’s named executive officers as follows: 1 Year 2 Years 3 Years Abstain Broker Non-Votes ──────────────────────────────────────────────────────────────────────── 22,443,829 10,501 76,086,572 919,024 12,986,028